2024-05-21
07:58 |
|
|
Evolution of invasive pneumococcal disease by serotype 3 in adults : a Spanish three-decade retrospective study
/
Calvo-Silveria, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
González-Díaz, Aida (Institut d'Investigació Biomèdica de Bellvitge) ;
Grau, Inmaculada (Institut d'Investigació Biomèdica de Bellvitge) ;
Marimón, José María (Hospital Donostia) ;
Cercenado, Emilia (Hospital General Universitario Gregorio Marañón) ;
Quesada, M.Dolores (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Casabella Pernas, Antonio (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Nieves Larrosa, María (Hospital Universitari Vall d'Hebron) ;
Yuste, José (Instituto de Salud Carlos III) ;
Berbel, Dàmaris (Institut d'Investigació Biomèdica de Bellvitge) ;
Alonso, Marta (Hospital Donostia) ;
Tubau, Fe (Institut d'Investigació Biomèdica de Bellvitge) ;
Belman, Sophie (Barcelona Supercomputing Center - Centro Nacional de Supercomputación) ;
Cadenas-Jiménez, Irene (Institut d'Investigació Biomèdica de Bellvitge) ;
Martín-Galiano, Antonio J. (Instituto de Salud Carlos III) ;
Domínguez, M.Ángeles (Institut d'Investigació Biomèdica de Bellvitge) ;
Martí, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
Liñares Louzao, Josefina (Institut d'Investigació Biomèdica de Bellvitge) ;
Pallarés, Román (Institut d'Investigació Biomèdica de Bellvitge) ;
Càmara, Jordi (Institut d'Investigació Biomèdica de Bellvitge) ;
Ardanuy, Carmen (Institut d'Investigació Biomèdica de Bellvitge) ;
Universitat Autònoma de Barcelona
Background: Invasive pneumococcal disease due to serotype 3 (S3-IPD) is associated with high mortality rates and long-term adverse effects. The introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) into the Spanish paediatric immunisation programme has not led to a decrease in the adult S3-IPD. [...]
2024 -  10.1016/j.lanepe.2024.100913
The Lancet Regional Health - Europe, Vol. 41 (june 2024) , p. 100913
|
|
2024-05-15
09:45 |
|
18 p, 4.4 MB |
Multiplex Analysis of CircRNAs from Plasma Extracellular Vesicle-Enriched Samples for the Detection of Early-Stage Non-Small Cell Lung Cancer
/
Pedraz-Valdunciel, Carlos (Institut Germans Trias i Pujol) ;
Giannoukakos, Stavros (Universidad de Granada) ;
Giménez-Capitán, A. (Dexeus University Hospital) ;
Fortunato, D. (Exosomics SpA) ;
Filipska, Martyna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bertran-Alamillo, J. (Dexeus University Hospital) ;
Bracht, J.W.P. (University of Amsterdam) ;
Drozdowskyj, A. (Dexeus University Institute) ;
Valarezo, J. (Dexeus University Hospital) ;
Zarovni, N. (Exosomics SpA) ;
Fernandez Hilario, Alberto (University of Granada) ;
Hackenberg, M. (Universidad de Granada) ;
Aguilar-Hernández, A. (Dexeus University Institute) ;
Molina-Vila, Miguel Ángel (Dexeus University Hospital) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Background: The analysis of liquid biopsies brings new opportunities in the precision oncology field. Under this context, extracellular vesicle circular RNAs (EV-circRNAs) have gained interest as biomarkers for lung cancer (LC) detection. [...]
2022 - 10.3390/pharmaceutics14102034
Pharmaceutics, Vol. 14 Núm. 10 (october 2022) , p. 2034
|
|
2024-04-24
10:48 |
|
14 p, 8.5 MB |
Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes
/
García Loza, Iván (Institut de Recerca Sant Pau) ;
Perna-Barrull, David (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aguilera, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Almenara-Fuentes, Lidia (Ahead Therapeutics SL) ;
Gómez Muñoz, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Greco, Daniela (Ahead Therapeutics SL) ;
Vila, María (Ahead Therapeutics SL) ;
Salvado, Miriam (Ahead Therapeutics SL) ;
Mancera Arteu, Montserrat (Ahead Therapeutics SL) ;
Olszowy, Michael W. (Sartorius Stedim North America. Inc.) ;
Petriz, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Dalmases, Martí (Ahead Therapeutics SL) ;
Rodriguez-Vidal, Sílvia (Ahead Therapeutics SL) ;
Barneda Zahonero, Bruna (Ahead Therapeutics SL) ;
Vives Pi, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Type 1 diabetes (T1D) results from a breakdown in immunological tolerance, with pivotal involvement of antigen-presenting cells. In this context, antigen-specific immunotherapies have been developed to arrest autoimmunity, such as phosphatidylserine (PS)-liposomes. [...]
2024 - 10.1016/j.jaut.2024.103196
Journal of autoimmunity, Vol. 145 (may 2024) , p. 103196
|
|
2024-04-24
04:32 |
|
10 p, 1.6 MB |
Gut microbial dysbiosis in patients with Cushing's disease in long-term remission. Relationship with cardiometabolic risk
/
Valassi, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Manichanh, Chaysavanh (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Amodru, Vincent (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Fernández, Pedro González (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Gaztambide, Sonia (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Yañez, Francisca (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martel-Duguech, Luciana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Puig Domingo, Manuel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Webb, Susan M. (Universitat Autònoma de Barcelona. Departament de Medicina)
Patients with Cushing's disease (CD) in remission maintain an increased cardiovascular risk. Impaired characteristics of gut microbiome (dysbiosis) have been associated with several cardiometabolic risk factors. [...]
2023 - 10.3389/fendo.2023.1074757
Frontiers in endocrinology, Vol. 14 (june 2023)
|
|
2024-04-24
04:32 |
|
10 p, 715.9 KB |
Influence of body mass index on recurrence of atrial fibrillation after electrical cardioversion
/
Ligero, Carmen (Hospital Universitari de Sant Joan, Universitat Rovira i Virgili) ;
Bazán, Víctor (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Guerra, José Maria (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Rodríguez-Mañero, Moisés (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Viñolas, Xavier (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Alegret i Colomé, Josep Maria (Hospital Universitari de Sant Joan, Universitat Rovira i Virgili) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Several studies have shown an independent relationship between body mass index (BMI) and the incidence of atrial fibrillation (AF). However, little is known about the influence of BMI on AF recurrence after electrical cardioversion (ECV). [...]
2023 - 10.1371/journal.pone.0291938
PloS one, Vol. 18 (september 2023)
|
|
2024-04-24
04:32 |
|
15 p, 1.7 MB |
Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia : A Retrospective Observational Study
/
Garrido-Alejos, Gemma (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Saborit-Canals, Guillem (Servei Català de la Salut) ;
Guarga, Laura (Servei Català de la Salut) ;
de Pando, Thais (Institut d'Investigació Biomèdica de Bellvitge) ;
Umbria, Miriam (Servei Català de la Salut) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Feliu, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Pontes García, Caridad (Institut d'Investigació Biomèdica de Bellvitge) ;
Vallano, Antoni (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
In this study, we examined the prescription patterns and pharmaceutical costs for treatments of multiple myeloma (MM) in Catalonia's public healthcare system over the past decade. MM is a complex and costly disease for which substantial pharmacological innovation has recently been introduced, and we aimed to understand how treatment choices and expenses have evolved. [...]
2023 - 10.3390/cancers15225338
Cancers, Vol. 15 (november 2023)
|
|
2024-04-24
04:32 |
|
15 p, 845.3 KB |
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease : An Observational Study from the ENEIDA Registry and Systematic Review
/
Puig, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Masnou, Helena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mesonero, Francisco (Hospital Universitario Ramón y Cajal (Madrid)) ;
Menchén, Luís (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Bujanda, Luis (Universidad del País Vasco) ;
Castro, Jesús (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
González-Partida, Irene (Hospital Puerta de Hierro (Madrid)) ;
Vicente, Raquel (Hospital Universitario Miguel Servet) ;
González-Muñoza, Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Iborra, Marisa (Hospital Universitari i Politècnic La Fe (València)) ;
Sierra Ausín, Mónica (Complejo Asistencial Universitario de León) ;
Huguet, José María (Hospital General Universitario de Valencia) ;
García García, María José (Universidad de Cantabria) ;
de Francisco, Ruth (Hospital Universitario Central de Asturias) ;
García-Alonso, Francisco Javier (Hospital Río Hortega) ;
Mañosa Ciria, Míriam (Hospital Universitario Ramón y Cajal (Madrid)) ;
Domènech, Eugeni (Universitat Autònoma de Barcelona. Departament de Medicina)
Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD. [...]
2023 - 10.3390/jcm12237366
Journal of clinical medicine, Vol. 12 (november 2023)
|
|
2024-04-24
04:32 |
|
29 p, 1.3 MB |
Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain
/
Nomah, Daniel Kwakye (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Reyes-Urueña, Juliana (Catalunya. Generalitat) ;
Alonso, Lucía (Catalunya. Generalitat) ;
Díaz, Yesika (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Moreno-Fornés, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Aceitón, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bruguera Riera, Andreu (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martín-Iguacel, Raquel (Catalunya. Generalitat) ;
Imaz, Arkaitz (Institut d'Investigació Biomèdica de Bellvitge) ;
Gutierrez, Mª del Mar (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Román, Ramón W. (Agència de Qualitat i Avaluació Sanitàries de Catalunya) ;
Suanzes, Paula (Hospital Universitari Vall d'Hebron) ;
Ambrosioni, Juan (Hospital Clínic i Provincial de Barcelona) ;
Casabona-Barbarà, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Miró, José M (Hospital Clínic i Provincial de Barcelona) ;
Llibre, Josep M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
People with HIV (PWH) may be more susceptible to SARS-CoV-2 infection and worse clinical outcomes. We investigated the disparity in SARS-CoV-2 vaccination coverage between PWH and those without HIV (PWoH) in Catalonia, Spain, assessing primary and monovalent booster vaccination coverage from December 2021 to July 2022. [...]
2023 - 10.3390/vaccines12010044
Vaccines (Basel), Vol. 12 (december 2023)
|
|
2024-04-24
04:32 |
|
10 p, 673.5 KB |
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors : A Retrospective, Multinational, Multicentre Study
/
Torres, Tiago (University of Porto, Portugal) ;
Chiricozzi, Andrea (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Puig Sanz, Lluís (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Lé, Ana Maria (Centro Académico Clínico ICBAS - CHP, Porto, Portugal) ;
Marzano, Angelo Valerio (Università degli Studi di Milano, Italy) ;
Dapavo, Paolo (University of Turin, Italy) ;
Dauden, Esteban (Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid) ;
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Lazaridou, Elizabeth (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Duarte, Gleison (Instituto Bahiano de Imunoterapias-IBIS, Salvador, Brazil) ;
Carvalho, André V. E. (Hospital Moinhos de Vento, Porto Alegre, Brazil) ;
Romiti, Ricardo (University of São Paulo, Brazil) ;
Rompoti, Natalia (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Teixeira, Laetitia (Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal) ;
Abreu, Miguel (University of Porto, Portugal) ;
Ippoliti, Elena (Università Cattolica del Sacro Cuore, Rome, Italy) ;
Maronese, Carlo Alberto (Università degli Studi di Milano, Italy) ;
Llamas-Velasco, Mar (Hospital Universitario de la Princesa (Madrid)) ;
Vilarrasa-Rull, Eva (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
del Alcázar, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Daponte, Athina-Ioanna (Aristotle University School of Medicine, Thessaloniki, Greece) ;
Papoutsaki, Marina (University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, Athens, Greece) ;
Carugno, Andrea (ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Bellinato, Francesco (University Hospital of Verona (Itàlia)) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. [...]
2024 - 10.1007/s40257-024-00845-4
American Journal of Clinical Dermatology, Vol. 25, Num. 2 (march 2024) , p. 333-342
|
|
2024-04-24
04:31 |
|
18 p, 1.0 MB |
Evaluating Osteoporosis in Chronic Kidney Disease : Both Bone Quantity and Quality Matter
/
Lloret, Maria Jesus (Institut de Recerca Sant Pau) ;
Fusaro, Maria (University of Padua) ;
Jørgensen, Hanne S. (Aalborg University Hospital (Dinamarca)) ;
Haarhaus, Mathias (Diaverum AB) ;
Gifre, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Alfieri, Carlo Maria (University of Milan) ;
Massó, Elisabet (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
D'Marco, Luis (Universidad CEU Cardenal Herrera) ;
Evenepoel, Pieter (KU Leuven) ;
Bover, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Bone strength is determined not only by bone quantity [bone mineral density (BMD)] but also by bone quality, including matrix composition, collagen fiber arrangement, microarchitecture, geometry, mineralization, and bone turnover, among others. [...]
2024 - 10.3390/jcm13041010
Journal of clinical medicine, Vol. 13 (february 2024)
|
|
|
|
|
visitant ::
identificació
Estadístiques d'ús
Els més consultats
